APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pulmonary Embolism Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Pulmonary Embolism Drug Market Outlook and Growth Opportunities 2026

26 December 2025198 pages

Choose your research edition.

Industry ResearchPulmonary Embolism Drug Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Pulmonary Embolism Drug Industry Growth and Trends Forecast to 203293 pages · $3,450 USDMarket StructureGlobal Pulmonary Embolism Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pulmonary Embolism Drug Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Pulmonary Embolism Drug Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Pulmonary Embolism Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Pulmonary Embolism Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Pulmonary Embolism Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pulmonary Embolism Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Pulmonary Embolism Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Pulmonary Embolism Drug market include F. Hoffmann-La Roche Ltd., Genentech, Inc., Verseon Corp, Dong-A Socio Holdings Co. Ltd. and Accu-Break Pharmaceuticals, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Pulmonary Embolism Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pulmonary Embolism Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pulmonary Embolism Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Pulmonary Embolism Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Pulmonary Embolism Drug Segment by Company

F. Hoffmann-La Roche Ltd.

Genentech, Inc.

Verseon Corp

Dong-A Socio Holdings Co. Ltd.

Accu-Break Pharmaceuticals, Inc.

Pulmonary Embolism Drug Segment by Type

DS-1040

DS-9231

TRX-1

Others

Pulmonary Embolism Drug Segment by Application

Hospital

Clinic

Others

Pulmonary Embolism Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Pulmonary Embolism Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Pulmonary Embolism Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Pulmonary Embolism Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Pulmonary Embolism Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pulmonary Embolism Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pulmonary Embolism Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pulmonary Embolism Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Pulmonary Embolism Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Pulmonary Embolism Drug industry.

Chapter 3: Detailed analysis of Pulmonary Embolism Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Pulmonary Embolism Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Pulmonary Embolism Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Pulmonary Embolism Drug Industry Trends Table 2. Pulmonary Embolism Drug Industry Drivers Table 3. Pulmonary Embolism Drug Industry Opportunities and Challenges Table 4. Pulmonary Embolism Drug Industry Restraints Table 5. Global Pulmonary Embolism Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Pulmonary Embolism Drug Revenue Share by Company (2021-2026) Table 7. Global Pulmonary Embolism Drug Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Pulmonary Embolism Drug Sales Volume Share by Company (2021-2026) Table 9. Global Pulmonary Embolism Drug Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Pulmonary Embolism Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Pulmonary Embolism Drug Key Company Manufacturing Base & Headquarters Table 12. Global Pulmonary Embolism Drug Company, Product Type & Application Table 13. Global Pulmonary Embolism Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Pulmonary Embolism Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of DS-1040 Table 18. Significant Companies of DS-9231 Table 19. Significant Companies of TRX-1 Table 20. Significant Companies of Others Table 21. Global Pulmonary Embolism Drug Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 22. Global Pulmonary Embolism Drug Sales Volume by Type (2021-2026) & (W Units) Table 23. Global Pulmonary Embolism Drug Sales Volume by Type (2027-2032) & (W Units) Table 24. Global Pulmonary Embolism Drug Sales Volume Share by Type (2021-2026) Table 25. Global Pulmonary Embolism Drug Sales Volume Share by Type (2027-2032) Table 26. Global Pulmonary Embolism Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Pulmonary Embolism Drug Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Pulmonary Embolism Drug Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Pulmonary Embolism Drug Sales Value Share by Type (2021-2026) Table 30. Global Pulmonary Embolism Drug Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Hospital Table 32. Significant Companies of Clinic Table 33. Significant Companies of Others Table 34. Global Pulmonary Embolism Drug Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 35. Global Pulmonary Embolism Drug Sales Volume by Application (2021-2026) & (W Units) Table 36. Global Pulmonary Embolism Drug Sales Volume by Application (2027-2032) & (W Units) Table 37. Global Pulmonary Embolism Drug Sales Volume Share by Application (2021-2026) Table 38. Global Pulmonary Embolism Drug Sales Volume Share by Application (2027-2032) Table 39. Global Pulmonary Embolism Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Pulmonary Embolism Drug Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Pulmonary Embolism Drug Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Pulmonary Embolism Drug Sales Value Share by Application (2021-2026) Table 43. Global Pulmonary Embolism Drug Sales Value Share by Application (2027-2032) Table 44. Global Pulmonary Embolism Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 45. Global Pulmonary Embolism Drug Sales by Region (2021-2026) & (W Units) Table 46. Global Pulmonary Embolism Drug Sales Market Share by Region (2021-2026) Table 47. Global Pulmonary Embolism Drug Sales by Region (2027-2032) & (W Units) Table 48. Global Pulmonary Embolism Drug Sales Market Share by Region (2027-2032) Table 49. Global Pulmonary Embolism Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Pulmonary Embolism Drug Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Pulmonary Embolism Drug Sales Value Share by Region (2021-2026) Table 52. Global Pulmonary Embolism Drug Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Pulmonary Embolism Drug Sales Value Share by Region (2027-2032) Table 54. Global Pulmonary Embolism Drug Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global Pulmonary Embolism Drug Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global Pulmonary Embolism Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 57. Global Pulmonary Embolism Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Pulmonary Embolism Drug Sales by Country (2021-2026) & (W Units) Table 59. Global Pulmonary Embolism Drug Sales Market Share by Country (2021-2026) Table 60. Global Pulmonary Embolism Drug Sales by Country (2027-2032) & (W Units) Table 61. Global Pulmonary Embolism Drug Sales Market Share by Country (2027-2032) Table 62. Global Pulmonary Embolism Drug Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Pulmonary Embolism Drug Sales Value Market Share by Country (2021-2026) Table 64. Global Pulmonary Embolism Drug Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Pulmonary Embolism Drug Sales Value Market Share by Country (2027-2032) Table 66. F. Hoffmann-La Roche Ltd. Company Information Table 67. F. Hoffmann-La Roche Ltd. Business Overview Table 68. F. Hoffmann-La Roche Ltd. Pulmonary Embolism Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. F. Hoffmann-La Roche Ltd. Pulmonary Embolism Drug Product Portfolio Table 70. F. Hoffmann-La Roche Ltd. Recent Development Table 71. Genentech, Inc. Company Information Table 72. Genentech, Inc. Business Overview Table 73. Genentech, Inc. Pulmonary Embolism Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Genentech, Inc. Pulmonary Embolism Drug Product Portfolio Table 75. Genentech, Inc. Recent Development Table 76. Verseon Corp Company Information Table 77. Verseon Corp Business Overview Table 78. Verseon Corp Pulmonary Embolism Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Verseon Corp Pulmonary Embolism Drug Product Portfolio Table 80. Verseon Corp Recent Development Table 81. Dong-A Socio Holdings Co. Ltd. Company Information Table 82. Dong-A Socio Holdings Co. Ltd. Business Overview Table 83. Dong-A Socio Holdings Co. Ltd. Pulmonary Embolism Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Dong-A Socio Holdings Co. Ltd. Pulmonary Embolism Drug Product Portfolio Table 85. Dong-A Socio Holdings Co. Ltd. Recent Development Table 86. Accu-Break Pharmaceuticals, Inc. Company Information Table 87. Accu-Break Pharmaceuticals, Inc. Business Overview Table 88. Accu-Break Pharmaceuticals, Inc. Pulmonary Embolism Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Accu-Break Pharmaceuticals, Inc. Pulmonary Embolism Drug Product Portfolio Table 90. Accu-Break Pharmaceuticals, Inc. Recent Development Table 91. Key Raw Materials Table 92. Raw Materials Key Suppliers Table 93. Pulmonary Embolism Drug Distributors List Table 94. Pulmonary Embolism Drug Customers List Table 95. Research Programs/Design for This Report Table 96. Authors List of This Report Table 97. Secondary Sources Table 98. Primary Sources List of Figures Figure 1. Pulmonary Embolism Drug Product Image Figure 2. Global Pulmonary Embolism Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pulmonary Embolism Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Pulmonary Embolism Drug Sales (2021-2032) & (W Units) Figure 5. Global Pulmonary Embolism Drug Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Pulmonary Embolism Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. DS-1040 Image Figure 10. DS-9231 Image Figure 11. TRX-1 Image Figure 12. Others Image Figure 13. Global Pulmonary Embolism Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 14. Global Pulmonary Embolism Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Pulmonary Embolism Drug Sales Volume Share by Type (2021-2032) Figure 16. Global Pulmonary Embolism Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Pulmonary Embolism Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Pulmonary Embolism Drug Sales Value Share by Type (2021-2032) Figure 19. Hospital Image Figure 20. Clinic Image Figure 21. Others Image Figure 22. Global Pulmonary Embolism Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 23. Global Pulmonary Embolism Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Pulmonary Embolism Drug Sales Volume Share by Application (2021-2032) Figure 25. Global Pulmonary Embolism Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Pulmonary Embolism Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Pulmonary Embolism Drug Sales Value Share by Application (2021-2032) Figure 28. Global Pulmonary Embolism Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 29. Global Pulmonary Embolism Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Pulmonary Embolism Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Pulmonary Embolism Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Pulmonary Embolism Drug Sales Value (2021-2032) & (US$ Million) Figure 33. North America Pulmonary Embolism Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Pulmonary Embolism Drug Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Pulmonary Embolism Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Pulmonary Embolism Drug Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Pulmonary Embolism Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Pulmonary Embolism Drug Sales Value (2021-2032) & (US$ Million) Figure 39. South America Pulmonary Embolism Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Pulmonary Embolism Drug Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Pulmonary Embolism Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Pulmonary Embolism Drug Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Pulmonary Embolism Drug Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • DS-1040
  • DS-9231
  • TRX-1
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • Verseon Corp
  • Dong-A Socio Holdings Co. Ltd.
  • Accu-Break Pharmaceuticals, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Pulmonary Embolism Drug Sales Value (2021-2032)
  4. 1.2.2 Global Pulmonary Embolism Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Pulmonary Embolism Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Pulmonary Embolism Drug Market Dynamics
  1. 2.1 Pulmonary Embolism Drug Industry Trends
  2. 2.2 Pulmonary Embolism Drug Industry Drivers
  3. 2.3 Pulmonary Embolism Drug Industry Opportunities and Challenges
  4. 2.4 Pulmonary Embolism Drug Industry Restraints
3 Pulmonary Embolism Drug Market by Company
  1. 3.1 Global Pulmonary Embolism Drug Company Revenue Ranking in 2025
  2. 3.2 Global Pulmonary Embolism Drug Revenue by Company (2021-2026)
  3. 3.3 Global Pulmonary Embolism Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Pulmonary Embolism Drug Average Price by Company (2021-2026)
  5. 3.5 Global Pulmonary Embolism Drug Company Ranking (2024-2026)
  6. 3.6 Global Pulmonary Embolism Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Pulmonary Embolism Drug Company Product Type and Application
  8. 3.8 Global Pulmonary Embolism Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Pulmonary Embolism Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Pulmonary Embolism Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Pulmonary Embolism Drug Market by Type
  1. 4.1 Pulmonary Embolism Drug Type Introduction
  2. 4.1.1 DS-1040
  3. 4.1.2 DS-9231
  4. 4.1.3 TRX-1
  5. 4.1.4 Others
  6. 4.2 Global Pulmonary Embolism Drug Sales Volume by Type
  7. 4.2.1 Global Pulmonary Embolism Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Pulmonary Embolism Drug Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Pulmonary Embolism Drug Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Pulmonary Embolism Drug Sales Value by Type
  11. 4.3.1 Global Pulmonary Embolism Drug Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Pulmonary Embolism Drug Sales Value by Type (2021-2032)
  13. 4.3.3 Global Pulmonary Embolism Drug Sales Value Share by Type (2021-2032)
5 Pulmonary Embolism Drug Market by Application
  1. 5.1 Pulmonary Embolism Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Pulmonary Embolism Drug Sales Volume by Application
  6. 5.2.1 Global Pulmonary Embolism Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Pulmonary Embolism Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Pulmonary Embolism Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Pulmonary Embolism Drug Sales Value by Application
  10. 5.3.1 Global Pulmonary Embolism Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Pulmonary Embolism Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Pulmonary Embolism Drug Sales Value Share by Application (2021-2032)
6 Pulmonary Embolism Drug Regional Sales and Value Analysis
  1. 6.1 Global Pulmonary Embolism Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pulmonary Embolism Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Pulmonary Embolism Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Pulmonary Embolism Drug Sales by Region (2027-2032)
  5. 6.3 Global Pulmonary Embolism Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Pulmonary Embolism Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Pulmonary Embolism Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Pulmonary Embolism Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Pulmonary Embolism Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Pulmonary Embolism Drug Sales Value (2021-2032)
  12. 6.6.2 North America Pulmonary Embolism Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Pulmonary Embolism Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Pulmonary Embolism Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Pulmonary Embolism Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Pulmonary Embolism Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Pulmonary Embolism Drug Sales Value (2021-2032)
  21. 6.9.2 South America Pulmonary Embolism Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Pulmonary Embolism Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Pulmonary Embolism Drug Sales Value Share by Country, 2025 VS 2032
7 Pulmonary Embolism Drug Country-level Sales and Value Analysis
  1. 7.1 Global Pulmonary Embolism Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Pulmonary Embolism Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Pulmonary Embolism Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Pulmonary Embolism Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Pulmonary Embolism Drug Sales by Country (2027-2032)
  6. 7.4 Global Pulmonary Embolism Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Pulmonary Embolism Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Pulmonary Embolism Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Pulmonary Embolism Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Pulmonary Embolism Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Pulmonary Embolism Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 F. Hoffmann-La Roche Ltd.
  2. 8.1.1 F. Hoffmann-La Roche Ltd. Company Information
  3. 8.1.2 F. Hoffmann-La Roche Ltd. Business Overview
  4. 8.1.3 F. Hoffmann-La Roche Ltd. Pulmonary Embolism Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 F. Hoffmann-La Roche Ltd. Pulmonary Embolism Drug Product Portfolio
  6. 8.1.5 F. Hoffmann-La Roche Ltd. Recent Developments
  7. 8.2 Genentech, Inc.
  8. 8.2.1 Genentech, Inc. Company Information
  9. 8.2.2 Genentech, Inc. Business Overview
  10. 8.2.3 Genentech, Inc. Pulmonary Embolism Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Genentech, Inc. Pulmonary Embolism Drug Product Portfolio
  12. 8.2.5 Genentech, Inc. Recent Developments
  13. 8.3 Verseon Corp
  14. 8.3.1 Verseon Corp Company Information
  15. 8.3.2 Verseon Corp Business Overview
  16. 8.3.3 Verseon Corp Pulmonary Embolism Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Verseon Corp Pulmonary Embolism Drug Product Portfolio
  18. 8.3.5 Verseon Corp Recent Developments
  19. 8.4 Dong-A Socio Holdings Co. Ltd.
  20. 8.4.1 Dong-A Socio Holdings Co. Ltd. Company Information
  21. 8.4.2 Dong-A Socio Holdings Co. Ltd. Business Overview
  22. 8.4.3 Dong-A Socio Holdings Co. Ltd. Pulmonary Embolism Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Dong-A Socio Holdings Co. Ltd. Pulmonary Embolism Drug Product Portfolio
  24. 8.4.5 Dong-A Socio Holdings Co. Ltd. Recent Developments
  25. 8.5 Accu-Break Pharmaceuticals, Inc.
  26. 8.5.1 Accu-Break Pharmaceuticals, Inc. Company Information
  27. 8.5.2 Accu-Break Pharmaceuticals, Inc. Business Overview
  28. 8.5.3 Accu-Break Pharmaceuticals, Inc. Pulmonary Embolism Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Accu-Break Pharmaceuticals, Inc. Pulmonary Embolism Drug Product Portfolio
  30. 8.5.5 Accu-Break Pharmaceuticals, Inc. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Pulmonary Embolism Drug Value Chain Analysis
  2. 9.1.1 Pulmonary Embolism Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Pulmonary Embolism Drug Sales Mode & Process
  6. 9.2 Pulmonary Embolism Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Pulmonary Embolism Drug Distributors
  9. 9.2.3 Pulmonary Embolism Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst